Skip to content
DataLookout
Menu

EVOLVENCT06606340

A Long-term Observational Study Evaluating Eteplirsen, Golodirsen, or Casimersen in Routine Clinical Practice

StatusEnrolling by Invitation
PhaseNot specified
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 3 versions: 2 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 9 words
    • Primary endpoints: details revised at 1 of 6 entries
    • Trial sites expanded: 20 → 23 locations
    • Publications: details revised at 1 of 1 entry
  2. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Loss of Ambulation (LOA)
Timeframe: Up to 5 years
Time to Rise From the Floor (Supine to Stand)
Timeframe: Up to 5 years
Time to Walk/Run 10 Meters
Timeframe: Up to 5 years
Performance of Upper Limb Module for DMD 2.0 (PUL 2.0) Entry Item A
Timeframe: Up to 5 years
Pulmonary Function, as Measured by Forced Vital Capacity (FVC) (% Predicted)
Timeframe: Up to 5 years
Cardiac Function, Including Left Ventricular Ejection Fraction (LVEF) as Measured by Echocardiogram (ECHO)
Timeframe: Up to 5 years

Arms and interventions

Eteplirsen
Golodirsen
Casimersen

Drugs: Eteplirsen, Golodirsen, Casimersen

Sites

23 sites in 1 country